WEBULL
News
PLX
1.800
+3.45%
0.060
Weekly Report: what happened at PLX last week (1208-1212)?
Weekly Report · 1d ago
Weekly Report: what happened at PLX last week (1201-1205)?
Weekly Report · 12/08 09:39
Weekly Report: what happened at PLX last week (1124-1128)?
Weekly Report · 12/01 09:37
Weekly Report: what happened at PLX last week (1117-1121)?
Weekly Report · 11/24 09:40
Protalix BioTherapeutics Price Target Cut to $12.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 11/21 11:31
Protalix BioTherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/21 11:31
HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Lowers Price Target to $12
Benzinga · 11/21 11:21
Protalix price target lowered to $12 from $15 at H.C. Wainwright
TipRanks · 11/21 11:10
Weekly Report: what happened at PLX last week (1110-1114)?
Weekly Report · 11/17 09:40
Protalix BioTherapeutics Reports Strong Revenue Growth in 2025
TipRanks · 11/14 04:28
Protalix BioTherapeutics’ Earnings Call Highlights Growth and Challenges
TipRanks · 11/14 00:37
Protalix BioTherapeutics GAAP EPS of $0.03 misses by $0.03, revenue of $17.67M misses by $0.2M
Seeking Alpha · 11/13 11:53
Protalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate
Benzinga · 11/13 11:51
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
PR Newswire · 11/13 11:50
Earnings Scheduled For November 13, 2025
Benzinga · 11/13 11:11
Here are the major earnings before the open Thursday
Seeking Alpha · 11/12 23:00
Preview: Protalix BioTherapeutics's Earnings
Benzinga · 11/12 17:02
Protalix BioTherapeutics Q3 Earnings Preview
Seeking Alpha · 11/12 16:03
Weekly Report: what happened at PLX last week (1103-1107)?
Weekly Report · 11/10 09:39
Protalix Seeks EMA Re-examination for Elfabrio Dosing
TipRanks · 11/03 22:10
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.